A Comparison of Two Commercially Available Escherichia coli J5 Vaccines against E. coli Intramammary Challenge

Tomita, G.M.; Ray, C.H.; Nickerson, S.C.; Owens, W.E.; Gallo, G.

doi:10.3168/jds.s0022-0302(00)75112-5

Cited by 34 publications

(39 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunization with the J5 vaccine indeed increases antibody titers to E. coli J5 core antigens in serum and mammary secretions [50]. In a field study, high serum IgG1 titers against E. coli O111: B4 (J5) were associated with a decreased incidence of clinical coliform mastitis [51].…”

Section: Hypothesis 2: J5 Vaccinationmentioning

confidence: 99%

“…Thus, it can be hypothesized that J5 vaccination may protect against severe coliform mastitis by stimulation of specific antibody production against the common core antigen of Gram-negative bacteria, resulting in enhanced opsonization of bacteria and LPS. However, although increased serum and milk specific antibody titers are generally observed following J5 vaccination, a relation with the incidence or severity of mastitis has not always been established [15,50]. Further evidence to reject the hypothesis that increased antibody titers provide protection in J5-vaccinated cows, comes from the conclusion of Hill [14] that opsonins are not a limiting factor in the pathogenesis of coliform mastitis.…”

Section: Hypothesis 2: J5 Vaccinationmentioning

confidence: 99%

See 1 more Smart Citation

Potential mechanism of action of J5 vaccine in protection against severe bovine coliform mastitis

2002

View full text Add to dashboard Cite

-Coliform mastitis is one of the most difficult diseases to treat in the modern dairy industry. Curative therapy with antibiotics remains only moderately effective and depends on the stage at which the disease is treated. The most successful strategies for combating coliform mastitis appear to be prevention by hygienic management or prophylactic immunization. The severity of clinical symptoms of coliform mastitis has been shown to be reduced by immunization with the Escherichia coli J5 vaccine. However, although the J5 vaccine has been licensed in the United States for about 10 years, the immunological basis of its mechanism of action is still unknown. Until now, protection by J5 vaccination has often been explained by a straightforward mechanism of enhanced antibody production resulting in increased opsonization of coliform bacteria and lipopolysaccharides (LPS). The possibility that J5 vaccination could decrease risk factors for coliform mastitis such as impaired blood polymorphonuclear neutrophil leukocyte (PMN) diapedesis has never been investigated. This review provides arguments to support the hypothesis that J5 vaccination may reduce the severity of coliform mastitis by inducing a condition of mammary gland hyper-responsiveness, characterized by a T helper 1 (Th1) response and mediated by memory cells inside the mammary gland, finally resulting in enhanced PMN diapedesis upon an intramammary infection. dairy cow / coliform mastitis / J5 vaccine / T cell / immune response Résumé -Mécanismes d'action possibles du vaccin J5 dans la protection contre la mammite coliforme sévère de la vache laitière. La mammite coliforme est une des maladies les plus difficiles à traiter dans l'industrie laitière moderne. La thérapie curative avec des antibiotiques reste peu efficace, dépendant du stade de la maladie. Les stratégies les plus efficaces pour combattre la mammite semblent être la prévention par des mesures d'hygiène ou la prophylaxie vaccinale. La sévérité des symptômes cliniques de la mammite coliforme peut être réduite par immunisation avec le vaccin Escherichia coli J5. Cependant, alors que le vaccin J5 a été mis sur le marché aux États-Unis depuis (32) 9 2647321; fax: (32) 9 2647499; e-mail: christian.burvenich@rug.ac.be environ 10 ans, les bases immunologiques de son mécanisme d'action ne sont pas connues. Jusqu'à présent, la protection par le vaccin J5 a souvent été attribuée à un simple mécanisme de stimulation de la production d'anticorps résultant en une augmentation de l'opsonization des bactéries coliformes et des lipopolysaccharides (LPS). La possibilité que la vaccination avec J5 pourrait diminuer les facteurs de risque de la mammite coliforme, tels qu'une diapédèse insuffisante des leucocytes neutrophiles polymorphonucléaires (PMN) sanguins, n'a jamais été étudiée. Cet article de synthèse cite des arguments supportant l'hypothèse que la vaccination avec J5 pourrait réduire la sévérité de la mammite coliforme en induisant une hyper-sensibilité de la glande mammaire. Celle-ci serait caractér...

show abstract

Section: Hypothesis 2: J5 Vaccinationmentioning

confidence: 99%

Section: Hypothesis 2: J5 Vaccinationmentioning

confidence: 99%

Potential mechanism of action of J5 vaccine in protection against severe bovine coliform mastitis

2002

View full text Add to dashboard Cite

show abstract

“…Esta potencialização se deve ao aumento nos níveis de anticorpos no colostro e nas secreções mamárias que reconhecem E. coli, devido a vacinação com E. coli J5, diminuindo a suscetibilidade dos animais em adquirir o agente no período pré-parto, como proposto por Tomita et al (2000).…”

Section: Resultsunclassified

“…Os resultados do presente estudo demonstram que a imunização de vacas, com E. coli J5 pode influenciar na redução da ocorrência de casos clínicos de mastite, tanto no momento pós--parto imediato, quanto nos primeiros 100 dias de lactação. Estes achados condizem com o proposto por Tomita et al (2000), que relataram que o mecanismo de ação da vacinação com E. coli J5, contra as mastites clínicas causadas por E. coli, consiste na proteção por meio do aumento da opsonização do LPS bacteriano e aumento dos títulos de anticorpos séricos e no leite. Em um estudo de campo, altos títulos de IgG 1, no soro, contra E. coli J5, foram associados com diminuição na incidência de mastites clínicas por coliformes (Tyler et al 1988).…”

Section: Resultsunclassified

Utilização da vacina Escherichia coli J5 na imunização de vacas leiteiras contra mastites causadas por E. coli

et al. 2013

View full text Add to dashboard Cite

Pesq. Vet. Bras. 33(3):291-298, março 2013 291 RESUMO.-Avaliou-se a utilização da vacina Escherichia coli J5, na imunização de vacas leiteiras, para prevenção e controle da mastite causada por E. coli através da aná-lise da prevalência das infecções intramamárias (IMM) no pós-parto, ocorrência e intensidade dos casos clínicos de mastite nos primeiros 100 dias de lactação, influência na We evaluated the use of Escherichia coli J5 vaccine immunization in dairy cows for the prevention and control of mastitis caused by E. coli. Were analyzed the prevalence of postpartum intramammary infections (IMM), occurrence and severity of clinical cases of mastitis in the first 100 days of lactation, influence on somatic cell count (SCC) and milk production. The experimental group consisted of 187 animals that were divided into two groups, vaccinated and unvaccinated cows. Immunizations occurred 60 days before calving, 30 days before calving and the first week postpartum. On the day of drying and seven days after birth, samples were collected for microbiological diagnosis of mastitis pathogens. The occurrence of clinical cases was verified by testing during the milking and data was recorded related to the intensity and duration. Samples were collected monthly starting at day ten of lactation to evaluate the CCS. Milk production was recorded monthly for the first 100 days of lactation. It was found in the vaccinated group reduction in the prevalence of E. coli in the postpartum period, the occurrence of clinical cases of E. coli in the first 100 days of lactation as well the intensity of these clinical cases. There were no statistically significant differences in CCS, however vaccinated cows had higher milk production, compared to unvaccinated cows. Vaccination with E. coli J5 was effective in reducing the prevalence of intramammary infections (IMM) at calving, occurrence and intensity of clinical cases and an increase in milk production in the first 100 days of lactation. Utilização da vacina

show abstract

“…Esta possui um antígeno do núcleo lipopolissacarídeo (LPS) relativamente exposto, sendo este comum às demais bactérias Gramnegativas, capazes de estimular a resposta imune do animal contra esses patógenos. Geralmente, as vacinações coincidem com o período de maior risco de aquisição de infecções intramamárias por coliformes, ou seja, no início e no fim do período seco e após o parto (Tomita et al, 2000).…”

Section: Introductionunclassified

Utilização da vacina Escherichia coli J5 na imunização de novilhas leiteiras contra mastites causadas por E. coli

Gentilini¹,

Molina

Carvalho

2012

Arq. Bras. Med. Vet. Zootec.

View full text Add to dashboard Cite

show abstract

A Comparison of Two Commercially Available Escherichia coli J5 Vaccines against E. coli Intramammary Challenge

Cited by 34 publications

References 12 publications

Potential mechanism of action of J5 vaccine in protection against severe bovine coliform mastitis

Potential mechanism of action of J5 vaccine in protection against severe bovine coliform mastitis

Utilização da vacina Escherichia coli J5 na imunização de vacas leiteiras contra mastites causadas por E. coli

Utilização da vacina Escherichia coli J5 na imunização de novilhas leiteiras contra mastites causadas por E. coli

Contact Info

Product

Resources

About